|
May 13
|
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
|
|
May 13
|
Astellas CEO on Outlook Ahead of Trump's Pharma Tariffs
|
|
May 12
|
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
|
|
May 7
|
Notice of Nominees for Directors
|
|
May 1
|
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
|
|
Apr 3
|
Astellas Pharma and JFCR partner for oncology research
|
|
Feb 27
|
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
|
|
Feb 12
|
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
|
|
Feb 11
|
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
|
|
Feb 10
|
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
|
|
Feb 10
|
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
|